LBI-HTA - Publications - Search - Year: 2015
Number of items: 34.

Grössmann, N. and Wild, C. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 25th Prioritisation – 4th quarter 2015. HSO: 25th Prioritisation.

Winkler, R. and Reinsperger, I. and Piso, B. (2015): Effects of tangible and intangible incentives on health behavior, Part I: Definitions, theories and models – Part II: Overview of reviews covering 4 health issues. HTA-Projektbericht 83.

Fischer, S. and Kisser, A. (2015): Robot-assisted surgery: A systematic review of effectiveness and safety for elected indications and accumulating costs. HTA-Projektbericht 84.

Wild, C. (2015): Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation (MitraClip®, Carillon®, NeoChord DS1000). German short version of the correspondent EUnetHTA assessment. Decision Support Document 93.

Wild, C. and Khan, A. and Erdos, J. (2015): Sponsoring of Patient Initiatives in Austria. Systematic Analysis. Rapid Assessment 007b.

Mayer, J. (2015): Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction - German short version and update of the correspondent EUnetHTA assessment. Decision Support Document 91.

Rothschedl, E. and Nachtnebel, A. (2015): Pembrolizumab (Keytruda®) for the treatment of advanced melanoma. DSD: Horizon Scanning in Oncology 55.

Rothschedl, E and Nachtnebel, A (2015): Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy . DSD: Horizon Scanning in Oncology 52.

Kisser, A. and Naimer, Ch. (2015): Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2. HTA-Projektbericht 80b.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 24th Prioritization – 3rd quarter 2015. HSO: 24th Prioritisation.

Nachtnebel, A (2015): Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma. DSD: Horizon Scanning in Oncology 54.

Naimer, Ch. and Piso, B. (2015): Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review. Decision Support Document 92.

Wild, C. and Gregor-Patera, N. (2015): HTA-Strategy for Lithuania. Decision Support Document 90a.

Wild, C. (2015): Biodegradable stents for the treatment of refractory or recurrent benign oesophageal stenoses. Decision Support Document 89.

Rothschedl, E. and Nachtnebel, A. (2015): Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy. DSD: Horizon Scanning in Oncology 51.

Wild, C. and Gregor-Patera, N. and Stricka, M. and Karnickas, L. (2015): Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices. Decision Support Document 90.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology 23rd Prioritization – 2nd quarter 2015. HSO: 23rd Prioritisation.

Wild, C. and Küllinger, R. and Hintringer, K. (2015): The sponsoring of Austrian CME/continuing medical education for physicians. A systematic analysis of the CME-Database. Rapid Assessment 007a.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 22nd Prioritisation – 1st quarter 2015. HSO: 22nd Prioritisation.

Winkler, R. (2015): Injectable bulking agents for faecal incontinence. Decision Support Document 87.

Winkler, R. (2015): Transcatheter mitral valve-in-valve implantation. Decision Support Document 82.

Piso, B. and Reinsperger, I. (2015): Vaccination against human papillomavirus (HPV). Decision-aid for young women and girls. Decision Support Document 79.

Ujeyl, M. and Nachtnebel, A. (2015): Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma. DSD: Horizon Scanning in Oncology 50.

Fischer, S. and Zechmeister-Koss, I. (2015): Intrastromal corneal implants for ectatic corneal disorders. Decision Support Document 85.

Reinsperger, I. and Piso, B. (2015): Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB) (1st Update 2015). Decision Support Document 68/ 1. Update 2015.

Rothschedl, E. and Nachtnebel, A. (2015): Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Decision Support Document 84.

Kisser, A. and Kirisits, A. (2015): Endovascular embolization of unruptured intracranial aneurysms with flow diverters. Decision Support Document 83.

Erdos, J. and Mayer, J. (2015): Sphenopalatine Ganglion (SPG) stimulation of patients with therapy-resistant cluster headache. Decision Support Document 86.

Reinsperger, I. and Piso, B. (2015): Percutaneous left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation (2nd Update 2015). Decision Support Document 44/ 2. Update 2015.

Zechmeister-Koss, I. and Rothschedl, E. (2015): Fully bioresorbable scaffolds for coronary artery disease. Decision Support Document 81.

Wild, C. (2015): Hadron therapy in children: evidence synthesis for 15 paediatric tumours. Report based on Belgian (KCE) HTA report. Decision Support Document 88.

Wild, C. and Blagojevic, S. (2015): Annual Report 2014.

Wild, C. and Patera, N. and Küllinger, R. and Narath, M. (2015): PET/PET-CT Evidence for need based planning (in oncology indications). HTA-Projektbericht 77.

Nachtnebel, A. and Ujeyl, M. (2015): Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer. DSD: Horizon Scanning in Oncology 53.

This list was generated on Thu Jul 20 16:00:03 2017 CEST.